PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability…